Izokibep

Phase 3Small molecule

AACELYRIN Inc.

Izokibep is one of 135 small molecule programs targeting Anterior Uveitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

134

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anterior UveitisActive, not recruiting

Psoriatic ArthritisActive, not recruiting

Hidradenitis SuppurativaActive, not recruiting

UveitisActive, not recruiting

Anterior UveitisPhase 2

Active, not recruiting

Psoriatic ArthritisPhase 2/Phase 3

Active, not recruiting

Hidradenitis SuppurativaPhase 3

Active, not recruiting

UveitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

114 competitors in Psoriatic Arthritis

#DrugCompanyPhaseTrials

Bimzelx

UCB

Phase 3

9 2

Skyrizi

AbbVie

Phase 3

8 3

Jyseleca

Gilead

Phase 3

4 4

Keytruda

Merck & Co.

Phase 3

1 5

Taxol

Teva

Phase 3

1 6

Icotyde

Johnson & Johnson

Phase 3

1 7

Xeljanz

PPrism Pharmaceuticals

Phase 3

8 8

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 10

Paraplatin

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hidradenitis Suppurativa2 trials

Hidradenitis Suppurativa Study of Izokibep

Terminated·AACELYRIN Inc.·Phase 3·NCT05905783·258 enrolled

Hidradenitis Suppurativa Phase 2b Study of Izokibep

Completed·AACELYRIN Inc.·Phase 2·NCT05355805·205 enrolled

Uveitis1 trial

Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis

Terminated·AACELYRIN Inc.·Phase 2·NCT05384249·96 enrolled

Anterior Uveitis1 trial

A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis

Completed·AACELYRIN Inc.·Phase 2·NCT04706741·7 enrolled

Psoriatic Arthritis1 trial

Psoriatic Arthritis Study of Izokibep

Terminated·AACELYRIN Inc.·Phase 2/3·NCT05623345·351 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Izokibep. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Izokibep compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Izokibep. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ACELYRIN Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AACELYRIN Inc.

Izokibep

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hidradenitis Suppurativa2 trials

Uveitis1 trial

Anterior Uveitis1 trial

Psoriatic Arthritis1 trial

References

Drug Info

Quick Facts

Related News